RTP Mobile Logo
Data + Perspectives: Clinical Investigators Explore the Current and Future Management of ER-Positive Breast Cancer
Released March 2020

Proceedings from a satellite symposium during the 42nd annual San Antonio Breast Cancer Symposium. Featuring perspectives from Dr Harold J Burstein, Dr Matthew Goetz, Prof Stephen RD Johnston and Dr Joseph A Sparano. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer (BC).

    OVERVIEW OF ACTIVITY
    The long-term management of early and advanced ER-positive BC has been in a constant state of evolution over the past several years. A number of relevant clinical and regulatory developments coupled with many lingering practical management concerns and the activation of a multitude of clinical trials evaluating novel agents have challenged physicians and their support staffs as they attempt to deliver state-of-the-art care for this distinct patient population.

    These video proceedings from a CME symposium during the San Antonio Breast Cancer Symposium feature discussions with leading researchers with an expertise in BC regarding actual cases from their practices and the published data that drive clinical decision-making for patients in those and diverse other situations. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist medical oncologists and other healthcare professionals with the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Consider published research data, consensus-based guidelines and other peer-reviewed sources to inform the use of biomarkers and genomic classifiers to assess risk and customize therapy for patients with localized hormone receptor-positive BC.
    • Individualize the selection and sequence of systemic therapy for patients with newly diagnosed ER-positive metastatic BC (mBC), considering clinical presentation (eg, age, menopausal status, comorbidities, extent and sites of disease), prior treatment course (eg, de novo metastatic disease, type and duration of adjuvant therapy) and psychosocial status.
    • Appreciate the means by which the cyclin-dependent kinase (CDK) pathway contributes to BC proliferation and growth, and recognize how the inhibition of CDK4/6 has improved outcomes for patients with ER-positive metastatic disease.
    • Recall the FDA indications for the commercially available CDK4/6 inhibitors, and discern how these agents can be optimally employed in the nonresearch care of patients with ER-positive mBC.
    • Develop an optimal approach to local and systemic therapy for patients with ER-positive BC and CNS metastases, considering the implications of symptomatology, number of lesions and other relevant factors.
    • Appraise available research data and clinical investigators’ perspectives to formulate appropriate clinical recommendations for patients who experience disease progression on CDK4/6 inhibitors in combination with hormonal therapy.
    • Recognize the frequency of phosphoinositide-3 kinase pathway mutations in patients with ER-positive mBC, and assess published research data with the use of novel agents targeting these abnormalities.
    • Understand the side effects associated with existing and recently approved systemic therapies for ER-positive BC, and develop strategies to prevent or ameliorate toxicities to support quality of life and continuation of treatment.
    • Assess ongoing clinical research studies evaluating novel agents and treatment strategies under development for ER-positive BC, and counsel patients regarding the potential benefits of trial participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/SanAntonioBC19/ER/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Harold J Burstein, MD, PhD
    Professor of Medicine
    Harvard Medical School
    Breast Oncology Center
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    No relevant conflicts of interest to disclose.

    Matthew Goetz, MD
    Professor of Oncology and Pharmacology
    Mayo Clinic
    Rochester, Minnesota

    Advisory Committee: bioTheranostics Inc, Biovica, Context Therapeutics, Lilly, Novartis, Pfizer Inc, Sermonix Pharmaceuticals.

    Stephen RD Johnston, MA, PhD
    Professor of Breast Cancer Medicine and Head of Medical Oncology
    Consultant Medical Oncologist and Head of the Breast Unit
    The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research
    Chelsea, London, United Kingdom

    Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Lilly, Novartis, Pfizer Inc, Puma Biotechnology Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech, Lilly, Novartis, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech, Novartis, Pfizer Inc, Roche Laboratories Inc.

    Joseph A Sparano, MD
    Associate Chairman, Department of Oncology
    Montefiore Medical Center
    Associate Director for Clinical Research
    Albert Einstein Cancer Center
    Albert Einstein College of Medicine
    Bronx, New York

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Cardinal Heath, CStone Pharmaceuticals, Daiichi Sankyo Inc, Genentech, Novartis, Pfizer Inc, Roche Laboratories Inc; Contracted Research: Deciphera Pharmaceuticals Inc, Prescient Therapeutics, Radius Health Inc; Data and Safety Monitoring Board: Celgene Corporation, Roche Laboratories Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genomic Health Inc, Lilly and Novartis.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: March 2020
    Expiration date: March 2021

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):

Introduction

Use of Genomic Classifiers to Inform Therapeutic Decision-Making for Patients with ER-Positive Localized Breast Cancer (BC)

Optimizing the Use of CDK4/6 Inhibitors in the Management of ER-Positive Metastatic BC (mBC)

Current and Future Management of ER-Positive mBC After Disease Progression on CDK4/6 Inhibition

Novel Applications of CDK4/6 Inhibitors; Ongoing Clinical Trials

Select Publications